UPDATE 1-U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
March 14, 2019 at 09:32 AM EDT
The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.
